Pharmacology of intraperitoneal chemotherapy for gastrointestinal cancer and diffuse malignant peritoneal mesothelioma

Tristan D. Yan, Oswald A. Stuart, Dal Yoo, Paul H. Sugarbaker

Research output: Contribution to journalReview article

Abstract

Perioperative intraperitoneal chemotherapy in combination with cytoreductive surgery has been shown to be of benefit for treating selected patients with peritoneal surface malignancy. It has become a new standard of care in the management of diffuse malignant peritoneal mesothelioma and peritoneal dissemination of appendiceal malignancy. Numerous recent publications on carcinomatosis from colorectal cancer and gastric cancer identify groups of patients that would benefit from this local-regional approach for prevention and treatment of carcinomatosis. This review focuses on the pharmacological information regarding intraperitoneal chemotherapeutic agents commonly used by the gastrointestinal oncology service at the Washington Cancer Institute.

Original languageEnglish
Pages (from-to)41-53
Number of pages13
JournalCurrent Topics in Pharmacology
Volume10
Issue number2
Publication statusPublished - 2006
Externally publishedYes

Keywords

  • Cisplatin 5-fluorouracil
  • Doxorubicin
  • Intraperitoneal chemotherapy
  • Mitomycin C
  • Paclitaxel
  • Peritoneal surface malignancy

Fingerprint Dive into the research topics of 'Pharmacology of intraperitoneal chemotherapy for gastrointestinal cancer and diffuse malignant peritoneal mesothelioma'. Together they form a unique fingerprint.

  • Cite this